HIV vaccine Vacc-4x(…Immuno AS) Drug Due Diligence 2026

This HIV vaccine Vacc-4x(Bionor Immuno AS) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether HIV vaccine Vacc-4x(Bionor Immuno AS) can convert its Therapeutic vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	HIV vaccine Vacc-4x(Bionor Immuno AS) (query alias: HIV vaccine Vacc-4x(Bionor Immuno AS))
Modality / target	Therapeutic vaccine; Not disclosed; Immunostimulants, T lymphocytes stimulants
Highest global status	Phase 2
Originator	Bionor Immuno AS
Active developers	Celgene Corp.

The MCP disease footprint includes HIV Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02092116	Phase 1/2	Completed	26	Primary endpoint not disclosed in English source
NCT01712256	Phase 2	Completed	33	Primary endpoint not disclosed in English source
NCT01704781	Phase 1/2	Completed	36	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Phase 2; n=33; evaluation: Not stated in English source. Reported fields: VL set-point = 22035 copies/mL

A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Phase 1/2; n=36; evaluation: Not stated in English source. Reported fields: ITT(Mean) = 90.9 10^6 cells/L ; ITT(Mean) = 42.2 10^6 cells/L

Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART

Phase 2; n=33; evaluation: Not stated in English source. Reported fields: CT Vacc-4x 2012/1 VL set point, ITT(Mean) = 38455.0 copies/mL

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

HIV vaccine Vacc-4x(Bionor Immuno AS) addresses HIV Infections. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Dosage regimen for HIV vaccine”. The milestone feed surfaced a patent-application signal described as “Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (HIV) or for reducing the risk of developing acquired immunodeficiency syndrome (AIDS)”. The milestone feed surfaced a patent-application signal described as “Dosage regimen for HIV vaccine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO